Skip to main content
. 2020 Oct 5;11:568503. doi: 10.3389/fimmu.2020.568503

Figure 1.

Figure 1

Cross-positivity for (A) IgA–aCL, IgG–aCL, and IgM–aCL in 800 aCL-positive subjects; (B) IgA–aβ2GPⅠ, IgG–aβ2GPⅠ, and IgM–aβ2GPI in 886 aβ2GPⅠ-positive subjects; and (C) IgA–aPL (either IgA–aCL or IgA–aβ2GPⅠ was positive), IgG–aCL, IgM–aCL, IgG–aβ2GPⅠ, and IgM–aβ2GPI in 1082 aPL-positive subjects.